Emerging strategies for the treatment of hereditary metabolic storage disorders

Rejuvenation Research

Volumn 9, Issue 2, 2006, Pages 237-244

  Brady, Roscoe O ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; ALPHA GALACTOSIDASE; CHAPERONE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT;

BLOOD BRAIN BARRIER; CATABOLISM; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE MUTATION; GENE THERAPY; HUMAN; METABOLIC DISORDER; PRIORITY JOURNAL; STORAGE DISEASE;

1-DEOXYNOJIRIMYCIN; BONE MARROW TRANSPLANTATION; ENZYME INHIBITORS; FABRY DISEASE; GANGLIOSIDOSIS, GM1; GAUCHER DISEASE; GENE THERAPY; HUMANS; IMINO SUGARS; PIPERIDINES;

EID: 33744951603     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2006.9.237     Document Type: Conference Paper

References (35)

1. Brady RO, Kanfer JN, Shapiro, D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965;18:221-225.
2. Brady RO, Kanfer JN, Bradley RM, Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 1966;45:1112-1115.
3. Okada S, O'Brien JS. Generalized gangliosidosis: beta-galactosidase deficiency. Science 1968;160:1002-1004.
4. Kolodny EH, Brady RO, Volk BW. Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease. Biochem Biophys Res Commun 1969;37:526-531.
5. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-1167.
6. Suzuki Y, Suzuki K. Krabbe's globoid cell leukodystrophy: deficiency of galactocerebrosidase in serum, leukocytes, and fibroblasts. Science 1971;171:73-75.
7. Brady RO, Kanfer JN, Mock MB, Fredrickson DS. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci USA 1966;55:366-369.
8. Scriver CR, Beaudet AL, Sly WS, Valle D. The Metabolic & Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill, 2001.
9. Brady RO. Sphingolipidoses. N Engl J Med 1966;275:312-318.
10. Furbish FS, Blair HE, Shiloach J, Pentchev PG, Brady RO. Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration. Proc Natl Acad Sci USA 1977;74:3560-3563.
11. Furbish FS, Steer CJ, Krett NL, Barranger JA. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 1981:673:425-434.
12. Brady RO, Furbish FS. Enzyme replacement therapy: specific targeting of exogenous enzymes to storage cells. In: Martonosi AN, ed. Membranes and Transport, vol. 2. New York: Plenum, 1982:587-592.
13. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990;87:1913-1916.
14. Parker RI, Barton NW, Read EJ, Brady RO. Hematologic improvement in a patient with Gaucher's disease on long-term replacement therapy: evidence for decreased splenic sequestration and improved red blood cell survival. Am J Hematol 1991;38:130-137.
15. Barton NW, Brady RO, Dambrosia JM, DiBisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, Grewal RP, Yu K-T. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-1470.
16. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO. Enzyme therapy in Gaucher disease Type 1: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Int Med 1995;122:33-39.
17. Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, Brady RO, Barton NW, Schiffmann R. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001;138:539-547.
18. Prows CA, Sanchez N, Daugherty C, Gabowski GA. Gaucher disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997;71:16-21.
19. Zirzow GC, Sanchez OA, Murray GJ, Brady RO, Oldfield EH. Delivery, distribution and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Neurochemical Res 1999;24:301-305.
20. Lonser RR, Walbridge S, Murray GJ, Aizenberg MR, Vortmeyer AO, Aerts JMFG, Brady RO, Oldfield EH. Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease. Ann Neurol 2005;57:542-548.
21. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-1485.
22. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Med 1999;5:112-115.
23. Matsuda J, Suzuki O, Akihiro O, Yamamoto Y, Noguchi A, Takimoto K, Itoh M, Matsuzaki Y, Yasuda Y, Ogawa S, Sakat Y, Nanba E, Higaki K, Ogawa Y, Tominaga L, Ohno K, Iwasaki H, Watanabe H, Brady RO, Suzuki Y. Chemical chaperone therapy for brain pathology in GM1-gangliosidosis. Proc Natl Acad Sci USA 2003;100:15912-15917.
24. Dunbar C, Kohn D, Karlsson S, Barton N, Brady R, Cottler-Fox M, Crooks G, Emmons R, Esplin J, Leitman S, Lenarsky C, Nolta J, Parkman R, Pensiero M, Schiffmann R, Tolstoshev P, Weinberg K. Clinical Protocol: Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study. Hum Gene Ther 1996;7:231-253.
25. Davidson BL, Chiorini JA. Recombinant adeno-associated viral vector types 4 and 5. Preparation and application for CNS gene transfer. Methods Mol Med 2003;76:269-285.
26. Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 2003;4:353-364.
27. Jung S-C, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 2001;98:2676-2681.
28. Park J, Murray GJ, Limaye A, Quirk JM, Glederman MP, Brady RO, Qasba P. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci USA 2003;100:3450-3454.
29. Ziegler RJ, Lonning SM, Armentano D, Li C, Souza DW, Cherry M, Ford C, Barbon CM, Desnick RJ, Gao G, Wilson JM, Peluso R, Godwin S, Carter BJ, Gregory RJ, Wadsworth SC, Cheng SH. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther 2004;9:231-240.
30. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, Campbell Thompson M, Daly T, Sands MS. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001;8:1343-1346.
31. Vogler C, Galvin N, Levy B, Grubb J, Jiang J, Zhou XY, Sly WS. Transgene produces massive overexpression of human beta-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc Natl Acad Sci USA 2003;100:2669-2673.
32. Kay MA, Nakai H. Looking into the safety of AAV vectors. Nature 2003;424:251.
33. Miller DG, Petek LM, Russell DW. Adeno-associated virus vectors integrate at chromosome breakage sites. Nat Genet 2004;36:767-773.
34. Nakai H, Wu X, Fuess S, Storm TA, Munroe D, Montini E, Burgess SM, Grompe M, Kay MA. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 2005;79:3606-3614.
35. Bell P, Wang L, Lebherz C, Flieder DB, Bove MS, Wu D, Gao GP, Wilson JM, Wivel NA. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 2005;12:299-306.